Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
Lung Cancer Survival High for Patients With Early, Screen-Detected Tumors Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
Lung Cancer Screening Programs Hit the Mark on Eligibility Criteria However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
Study: Microwave Ablation for Lung Nodules Effective as Last Resort Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Long-term follow-up shows continued survival benefit as first-line treatment Aug 11, 2022
Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutations Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo Aug 10, 2022
Survey: 77% of Women With Lung Cancer Report Sexual Dysfunction Results show need to integrate sexual health into care, researcher says Aug 09, 2022
Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC Phase II trial supports neoadjuvant nivolumab plus chemotherapy Aug 09, 2022
New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC Overall survival benefit now demonstrated Aug 09, 2022
Low-Dose Sotorasib 'Lead-in' Strategy Promising in NSCLC Subset Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option Aug 08, 2022
Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC? Large randomized study shows non-inferiority to lobectomy Aug 08, 2022
Hearing Loss Plagues Cancer Survivors No Matter the Type of Chemo Ototoxicity reported in more than half of study patients who got platinum, taxanes, or both Aug 03, 2022
Lorlatinib Reduces CNS Progression in ALK-Positive NSCLC Post-hoc analysis of CROWN trial does find more central nervous system toxicity, however Jun 14, 2022
A Better Way to Irradiate Lethal CNS Metastases? Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread Jun 08, 2022
Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancer No change in survival when combined with atezolizumab and chemotherapy Jun 06, 2022
Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boost Phase II trial sees "synergistic benefit" with checkpoint blockade and anti-angiogenesis Jun 04, 2022
KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients Median survival surpasses 1 year in heavily pretreated population Jun 03, 2022
Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC Big increases in response, disease control with the addition of anti-CD73, anti-NKG2A agents May 02, 2022
Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLC Prolonged tumor response seen in 2-year analysis Apr 11, 2022
More Research Needed on Use of Premium Cigars, Report Finds These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
Dual HER2 Therapy Active in Previously Treated Lung Cancer Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancer Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
Tumor Volume-Adapted RT Leads to Good Lung Cancer Control With Low Toxicity No recurrence at 1 year in 90% of cases with primary tumors, metastases, synchronous disease Nov 02, 2021
Targeted RT Boosts PFS in Oligoprogressive Lung Cancer Fivefold improvement in NSCLC but no benefit in oligoprogressive breast cancer Oct 25, 2021
'You're Still Doing WHAT After Lung Cancer Surgery?!' But don't give up on hardened smokers, researcher urges Oct 19, 2021
Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs Oral tyrosine kinase inhibitor may serve patient population with high unmet need Oct 14, 2021
Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLC No PFS or OS improvement with consolidation nivolumab-ipilimumab after standard treatment Sep 29, 2021
